Pharmaceutical Applications of Nano-Niosomes in Drug, Vaccine and Gene Delivery
DOI:
https://doi.org/10.37285/ijpsn.2014.7.4.2Abstract
This review article describes recent advances in the field of nano-science related to niosomes, non-ionic surfactant vesicles (NSVs). Development trends in nanotechnology in health and medicine are expected to provide solutions to many of modern medicine's unsolved problems. Nanotechnology offers potential developments in therapeutics, diagnosis, cancer treatment, implantable materials, and tissue regeneration. The objective of this review is to provide a solid groundwork for anticipating the next phases of nanomedicine development, highlighting valuable perspective and find out the various areas where niosomes are applied. NSVs are the hydrated lipids composed mainly of different classes of non-ionic surfactants, introduced in the seventies as a cosmetic vehicle. Currently, niosomes are used as important new drug delivery systems by many research groups and also they are effective immunoadjuvants which some commercial forms are already available in the market. These vesicles are recently used as gene transfer vectors too.
Downloads
Metrics
Keywords:
Nanotechnology, Niosomes, DNA vaccines, Spans, NSVs.
Downloads
Published
How to Cite
Issue
Section
References
Abdelkader H, Ismail S, Kamal A and Alany RG (2010). Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery Pharmazie 65(11): 811-7.
Alvi IA, Madan J, Kaushik D, Sardana S, Pandey RS, Ali A (2011). Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release, and cytotoxicity analysis. Anticancer Drugs 22(8): 774-82.
Babu RJ, Singh M, Kanikkannan N editors (2006). Fatty Alcohols and Fatty Acids. Boca Raton, Fla, USA: CRC Press, Taylor & Francis Group.
Balasubramaniam A, Kumar V and Pillai K (2002). Formulation and in vivo evaluation of niosome-encapsulated daunorubicin hydrochloride. Drug Dev Ind Pharm 28: 1181-1193.
Bragagni M, Mennini N, Ghelardini C, Mura P (2012). Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting J Pharm Pharm Sci 15(1): 184-96.
Brewer J, Alexander J (1992). The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology 75: 570-575.
Caracciolo G et al., (2008). Effect of hydration on the structure of solid-supported Niosomal membranes investigated by in situ energy dispersive X-ray diffraction. Chem Phys Lett 462(4-6): 307-312.
Chambers MA et al., (2004). A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis. Vaccine 22(8): 1063-1071.
Chattaraj S, Das S (2003). Physicochemical characterization of influenza viral vaccine loaded surfactant vesicles. Drug Deliv 10(2): 73-77.
Chen H et al., (2009). Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin. J Control Release 139(1): 63-72.
Cosco D et al., (2009). Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil. Biomed Microdevice 11(5): 1115-1125.
Denet A, Vanbever R, Préat V (2004). Skin electroporation for transdermal and topical delivery. Advanced Drug Delivery Reviews 56(5): 659-674.
Devaraj G, Parakh S, Devraj R, Apte S, Rao B, Rambhau D (2002). Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Colloid Interface Sci 251: 360-365.
Di Marzio L, Esposito S, Federica R, Carlotta M, Maria C (2012). Polysorbate 20 vesicles as oral delivery system: in-vitro characterization. Colloid Surf B. 104: 200-206.
Dimitrijevic D, Lamandin C, Uchegbu IF, Shaw AJ, Florence AT (1997). The effect of monomers and micellar and vesicular forms of non-ionic surfactants (Solulan C24 and Solulan 16) on Caco-2 cell monolayers. J Pharm Pharmacol 49(6): 611-616.
Echegoyen LE, Hernandez JC, Kaifer AE, Gokel GW, Echegoyen L (1988). Aggregation of steroidal lariat ethers: the first example of nonionic liposomes (niosomes) formed from neutral crown ether compounds. J Chem Soc Chem Commun 12: 836-837.
ElBayoumi TA, Torchilin VP (2009). Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res 15(6): 1973-1980.
Elhissi A et al., (2013). Air-jet and vibrating-mesh nebulization of niosomes generated using a particulate-based proniosome technology. Int J Pharm 444: 193-199.
El-Kamel AH, Al-Fagih IM, Alsarra IA (2008). Effect of sonophoresis and chemical enhancers on testosterone transdermal delivery from solid lipid microparticles: an in vitro study. Current Drug Delivery 5(1): 20-26.
Engel E, Michiardi A, Navarro M, Lacroix D, Planell JA (2008). Nanotechnology in regenerative medicine: the materials side. Trends Biotechnol 26(1): 39-47.
Fang JY, Yu SY, Wu PC, Huang YB, Tsai YH (2001). In vitro skin permeation of estradiol from various proniosome formulations. Int J Pharm 215(1): 91-99.
Ferro VA, Stimson W (1998). Investigation into suitable carrier molecules for use in an anti-gonadotrophin releasing hormone vaccine. Vaccine 16(11): 1095-1102.
Ferro VA et al., (2004). Immune responses to a GnRH-based anti-fertility immunogen, induced by different adjuvants and subsequent effect on vaccine efficacy. Vaccine 22(8): 1024-31.
Foster T, Dorfman KD, Ted Davis H (2010). Giant biocompatible and biodegradable PEG–PMCL vesicles and microcapsules by solvent evaporation from double emulsion droplets. J Colloid Interface Sci 351(1): 140-150.
Grischke E et al., (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15(3): 440-449.
Gupta P et al., (2005). Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. Int J Pharm. 293: 73-82.
Hamilton A et al., (2002). EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer. Ann Oncol 13(6): 910-918.
Hashim F, El-Ridy M, Nasr M, Abdallah Y (2010). Preparation and characterization of niosomes containing ribavirin for liver targeting. Drug Deliv. 17(5): 282-287.
Hassan Y, Brewer J, Alexander J, Jennings R (1996). Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems. Vaccine 14(17): 1581-1589.
Huang Y, Chen J, Chen X, Gao J, Liang W. PE (2008). Gylated synthetic surfactant vesicles (Niosomes): novel carriers for oligonucleotides. J Mater Sci Mater Med. 19: 607-614.
Huang Y, Han G, Wang H, Liang W (2005). Cationic niosomes as gene carriers: preparation and cellular uptake in vitro. Pharmazie 60: 473-474.
Jain C, Vyas S (1995). Preparation and characterization of niosomes containing rifampicin for lung targeting. J Microencap 12: 401-407.
Jain S, Singh P, Mishra V, Vyas S (2005). Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B. Immunol Lett.101: 41-49.
Jain S, Vyas S (2006) Mannosylated niosomes as adjuvant-carrier system for oral mucosal immunization. J Liposome Res.16: 331-345.
Jain KK (2005). Nanotechnology in clinical laboratory diagnostics. Clin Chim Acta 358(1-2): 37-54.
Jin Y et al., (2013). Development of a novel niosomal system for oral delivery of Ginkgo biloba extract. Int J Nanomedicine 8: 421.
Junyaprasert V, Teeranachaideekul V, Supaperm T (2008). Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes. AAPS Pharm Sci Tech 9: 851-859.
Khositsuntiwong N et al., (2012). Enhancement of gene expression and melanin production of human tyrosinase gene loaded in elastic cationic niosomes. J Pharm Pharmacol 64(10): 1376-1385.
Kirby C, Gregoriadis G (1984). Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Nat Biotechnol 2(11): 979-984.
Kurmi BD, Kayat J, Gajbhiye V, Tekade RK, Jain NK (2010). Micro-and nanocarriers mediated lung targeting. Expert Opin Drug Deliv 7(7): 781-794.
Lee JW, Gadiraju P, Park JH, Allen MG, Prausnitz MR (2011). Microsecond thermal ablation of skin for transdermal drug delivery. Journal of Controlled Release. 154(1): 58-68.
LezamaDávila CM (1999). Vaccination of C57BL/10 mice against cutaneous leishmaniasis. Use of purified gp63 encapsulated into niosomes surfactants vesicles: a novel approach. Mem Inst Oswaldo Cruz. 94(1): 67-70.
Litzinger DC, Buiting AMJ, van Rooijen N, Huang L (1994). Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly (ethylene glycol) containing liposomes. Biochim Biophys Acta (BBA) - Biomembranes. 1190(1): 99-107.
Liu CH, Chang FY and Hung DK (2011). Terpene microemulsions for transdermal curcumin delivery: effects of terpenes and cosurfactants. Colloids and Surfaces B 82(1): 63-70.
Liu T and Guo R (2007). Structure and Transformation of the niosome prepared from PEG 6000/Tween 80/Span 80/H2O lamellar liquid crystal. Colloids Surf A Physicochem Eng Asp 295(1): 130-134.
Liu H and Webster TJ (2007). Nanomedicine for implants: a review of studies and necessary experimental tools. Biomaterials; 28(2): 354-369.
Lo C, Jahn A, Locascio L and Vreeland W (2010). Controlled self-assembly of monodisperse niosomes by microfluidic hydrodynamic focusing. Langmuir. 26: 8559-8566.
Mahor S, Gupta PN, Rawat A and Vyas SP (2007). A needle-free approach for topical immunization: antigen delivery via vesicular carrier system (s). Curr Med Chem 14(27): 2898-2910.
Maiti S, Paul S, Mondol R, Ray S, Sa B (2011). Nanovesicular Formulation of Brimonidine Tartrate for the Management of Glaucoma: in vitro and in vivo Evaluation. AAPS Pharm Sci Tech 12(2): 755-763.
Manosroi A, Chutoprapat R, Abe M, Manosroi J (2008). Characteristics of niosomes prepared by supercritical carbon dioxide (scCO2) fluid. Int J Pharm 352: 248-255.
Manosroi A, Jantrawut P, Manosroi J (2008). Anti-inflammatory activity of gel containing novel elastic niosomes entrapped with diclofenac diethylammonium. Int J Pharm 360(1-2): 156-63.
Manosroi A, Khositsuntiwong N, Götz F, Werner R, Manosroi J (2009). Transdermal enhancement through rat skin of luciferase plasmid DNA loaded in elastic nanovesicles. J Liposome Res 19: 91-98.
Manosroi A, Thathang K, Werner R, Schubert R, Manosroi J.(2008). Stability of luciferase plasmid entrapped in cationic bilayer vesicles. Int J Pharm. 356: 291-299.
Manosroi J, Khositsuntiwong N, Manosroi W, Götz F, Werner R, Manosroi A (2010). Enhancement of transdermal absorption, gene expression and stability of tyrosinase plasmid (pMEL34) - loaded elastic cationic niosomes: potential application in vitiligo treatment. J Pharm Sci 99: 3533-3541.
Masotti A et al.(2010) Novel Tween® 20 derivatives enable the formation of efficient pH-sensitive drug delivery vehicles for human hepatoblastoma. Bioorg Med Chem Lett 20(10): 3021-3025.
Meyer et al. (1998) Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J Biol Chem. 273(25): 15621-15627.
Mohamedi S, Brewer J, Alexander J, Heath A, Jennings R (2010). Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems. Vaccine 18(20): 2083-2094.
Mozafari RM (2005). Nanoliposomes: from fund amentals to recent developments. Oxford, UK. Trafford Publishing Ltd.
Mukherjee B, Patra B, Layek B, Mukherjee A (2007). Sustained release of acyclovir from nano-liposomes and nano-niosomes: An in vitro study. Int J Nanomedicine 2(2): 213-225.
Murdan S, Gregoriadis G, Florence A (1999). Sorbitan monostearate/polysorbate 20 organogels containing niosomes: a delivery vehicle for antigens. Eur J Pharm Sci 8: 177-186.
Nademi M, Mozaffari A, Farrokhabadi A (2011). A New Self Healing Method in Composite Laminates Using the Hollow Glass Fiber. Key Eng Mat. 471: 548-551.
Nasseri B (2005). Effect of cholesterol and temperature on the elastic properties of niosomal membranes. Int J Pharm. 300: 95-101.
Nie S, Xing Y, Kim GJ and Simons JW (2007). Nanotechnology applications in cancer. Biomed Engin. 9: 257-288.
Ning M, Guo Y, Pan H, Yu H, Gu Z (2005). Niosomes with sorbitan monoester as a carrier for vaginal delivery of insulin: Studies in rats. Drug Deliv 12(6): 399-407.
Obrenovic MM, Perrie Y, Gregoriadis G (1998). Entrapment of plasmid DNA into niosomes: characterization studies. J Pharm Pharmacol 50(S9): 155.
Okahata Y, Ando R, Kunitake T (1982). Phase Transition of the Bilayer Membrane of Synthetic Dialkyl Amphiphiles as Studied by Differential Scanning Calorimetry. Ber Bunsenges Phys Chem 85(8): 789-798.
Okumura Y, Iwata Y (2011). Electroformation of Giant Vesicles and Electrode Polarity. Bull Chem Soc Jpn 84(10): 1147-1149.
Pardakhty A, Moazeni E, Varshosaz J, Hajhashemi V, Najafabadi AR (2012). Pharmacokinetic study of niosome-loaded insulin in diabetic rats. DARU J Pharm Sci 19(6): 404-411.
Pardakhty A, Shakibaie M and Daneshvar H (2012). Preparation and evaluation of niosomes containing autoclaved Leishmania major: a preliminary study. J Microencapsul 29(3): 219-224.
Perrie Y, Barralet J, McNeil S and Vangala A (2004). Surfactant vesicle-mediated delivery of DNA vaccines via the subcutaneous route. Int J Pharm 284(1): 31-41.
Phillips CA and Michniak BB (1995). Transdermal delivery of drugs with differing lipophilicities using azone analogs as dermal penetration enhancers. J Pharm Sci 84(12): 1427-1433.
Priya B, Rashmi T and Bozena M (2006). Transdermal iontophoresis. Expert Opinion on Drug Delivery 3(1): 127-138.
Puglia C, Bonina F (2012). Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opinion on Drug Delivery. Biomed Res Int. 9(4): 429-441.
Ravouru N, Kondreddy P, Korakanchi D, Haritha M (2013). Formulation and evaluation of niosomal nasal drug delivery system of folic acid for brain targeting. Curr Drug Discov Technol. 10(4): 270-82.
Rentel C, Bouwstra J, Naisbett B, Junginger H (1999). Niosomes as a novel peroral vaccine delivery system. Int J Pharm. 186: 161-167.
Rogerson A, Cummings J, Florence A (1987). Adriamycin-loaded niosomes: drug entrapment, stability and release. J Microencap 4: 321-328.
Rungphanichkul N, Nimmannit U, Muangsiri W, Rojsitthisak P (2011). Preparation of curcuminoid niosomes for enhancement of skin permeation. Pharmazie 66(8): 570-5.
Sezgin-Bayindir Z, Yuksel N (2012). Investigation of Formulation Variables and Excipient Interaction on the Production of Niosomes. AAPS Pharm Sci Tech. 1-10.
Shi B, Fang C, Pei Y (2006). Stealth PEG PH DCA niosomes: Effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J Pharm Sci. 95(9): 1873-1887.
Suwakul W, Ongpipattanakul B, Vard hanabhuti N (2006). Preparation and characterization of propylthiouracil niosomes. J Liposome Res. 16(4): 391-401.
Talsma H, Steenbergen Mv, Borchert J, Crommelin D (1994). A novel technique for the one-step preparation of liposomes and nonionic surfactant vesicles without the use of organic solvents. Liposome formation in a continuous gas stream: the 'bubble' method. J Pharm Sci. 83: 276-280.
Tavano L, Vivacqua M, Carito V, Muz zalupo R, Caroleo MC, Nicoletta F (2013). Doxorubicin loaded magneto-niosomes for targeted drug delivery. Colloid Surf B. 102: 803-807.
Uchegbu I, Double J, Kelland L, Turton J, Florence A (1996). The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models. J Drug Target. 3: 399-409.
Uchegbu IF, Duncan R (1997). Niosomes containing N-(2-hydroxypropyl) metha crylamide copolymer-doxorubicin (PK1): effect of method of preparation and choice of surfactant on niosome characteristics and a preliminary study of body distribution. Int J Pharm. 155(1): 7-17.
Uchegbu IF, Vyas SP (1998). Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 172(1): 33-70.
Van Hal DA, Bouwstra JA, van Rensen A, Jeremiasse E, de Vringer T, Junginger HE (1996). Preparation and characterization of nonionic surfactant vesicles. J Colloid Interface Sci. 178(1): 263-273.
Vangala A, Kirby D, Rosenkrands I, Agger EM, Andersen P, Perrie Y (2006). A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterization, environmental scanning electron microscopy and immunisation studies in mice. J Pharm Pharmacol. 58(6): 787-799.
Vangala A, Bramwell VW, McNeil S, Christensen D, Agger EM and Perrie Y (2007). Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J Control Release 119(1): 102-110.
Varshosaz J, Pardakhty A, Hajhashemi V and Najafabadi A (2003). Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. Drug Deliv 10: 251-262.
Vauthey S, Santoso S, Gong H, Watson N and Zhang S (2002). Molecular self-assembly of surfactant-like peptides to form nanotubes and nanovesicles. Proc Natl Acad Sci. 99(8): 5355-5360.
Vyas S et al., (2005). Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int J Pharm. 296: 80-86.
Wang ZL (2003). Nanobelts, nanowires, and nano diskettes of semiconducting oxides-from materials to nanodevices. Adv Mater. 15(5): 432-436.
Wickline SA, Lanza GM (2003). Nanotechnology for molecular imaging and targeted therapy. Circulation.107(8): 1092-1095.
Yang D, Zhu J, Huang Z, Ren H, Zheng Z (2008). Synthesis and application of poly(ethylene glycol)-cholesterol (Chol-PEGm) conjugates in physicochemical characterization of nonionic surfactant vesicles. Colloid Surf B. 63(2): 192-199.
Yoshioka T, Skalko N, Gursel M, Gregoriadis G and Florence A (1995). A non-ionic surfactant vesicle-in-water-in-oil (v/w/o) system: potential uses in drug and vaccine delivery. J Drug Target. 2: 533-539.
Yoshioka T, Sternberg B and Florence A (1994). Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60, and 80) and a sorbitan triester (Span 85). Int J Pharm. 105: 1-6.
Zarif L, Gulik-Krzywicki T, Riess JG, Pucci B and Guedj C (1994). Alkyl and perfluoroalkyl glycolipid-based supramolecular assemblies. Colloids Surf A Physicochem Eng Asp. 84(1): 107-112.
Zidan AS, Rahman Z and Khan MA (2011). Product and process understanding of a novel pediatric anti-HIV tenofovir niosomes with a high-pressure homogenizer. Eur J Pharm Sci 44(1): 93-102.
